Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

苯达莫司汀 医学 套细胞淋巴瘤 内科学 中性粒细胞减少症 美罗华 耐受性 胃肠病学 不利影响 临床终点 弥漫性大B细胞淋巴瘤 人口 临床研究阶段 毒性 肿瘤科 药理学 临床试验 淋巴瘤 环境卫生
作者
Tycel Phillips,Stephen D. Smith,Wojciech Jurczak,Tadeusz Robak,Don A. Stevens,Charles M. Farber,John M. Pagel,Kami J. Maddocks,Ian W. Flinn,W Wiktor-Jędrzejczak,André Goy,Pier Luigi Zinzani,Jan Maciej Zaucha,Morton Coleman,Tianling Chen,Sun Ku Lee,Wei Liang,Anna Seto,Michael Wang
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 4144-4144 被引量:7
标识
DOI:10.1182/blood-2018-99-110617
摘要

Abstract Background: MCL is a subtype of NHL that remains largely incurable with conventional therapies; BR is standard first-line therapy. Acalabrutinib is a potent, highly selective, covalent Bruton tyrosine kinase inhibitor with minimal off-target activity. Acalabrutinib was approved by the FDA in October 2017 for patients with R/R MCL and ≥1 prior therapy. This ongoing, multicenter, open-label Phase 1b study assessed the safety and efficacy of acalabrutinib + BR in patients with TN or R/R MCL. Methods: Patients aged ≥18 y with ECOG PS ≤2 and adequate organ function were eligible; R/R patients had received ≥1 prior therapy. Patients received oral acalabrutinib 100 mg twice daily, plus B 90 mg/m2 intravenously (IV) on days 1 and 2 and R 375 mg/m2 IV on day 1 in each 28-day cycle. Acalabrutinib was given until disease progression (PD) or intolerance; BR was repeated every 28 days for up to 6 cycles. Patients with TN MCL who achieved partial or complete response (CR) received rituximab maintenance therapy (375 mg/m2 every other cycle for up to 12 doses starting on cycle 8). Dose-limiting toxicity (DLT) was evaluated in the first 6 patients per cohort (TN or R/R) after completing 1 cycle. If <2 patients had DLTs, cohorts were expanded. The primary endpoint was safety of acalabrutinib + BR. Secondary endpoints were overall response rate (ORR), duration of response (DOR) and progression-free survival (PFS). Pharmacokinetic evaluation was exploratory. Results: A total of 38 patients enrolled (TN, n=18; R/R, n=20); 63% were men; 55% were ≥65 y. At baseline, 100% of TN and 95% of R/R patients had ECOG PS ≤1; 89% and 95% had Ann Arbor stage IV disease, 44% and 60% had intermediate-risk and 11% and 15% had high-risk simplified MCL International Prognostic Index scores, respectively. The median number of prior therapies in the R/R cohort was 2 (range 1-4) and 45% were refractory (stable disease or PD) to most recent prior treatment. As of 4 May 2018, median time on study was 17.6 mo (range 0.6-23.1) for TN and 14.2 mo (range 1.2-23.6) for R/R patients; 78% of TN and 50% of R/R patients completed 6 cycles of BR with acalabrutinib. Across both cohorts, no DLTs were observed. Adverse events (AEs) of any grade in ≥30% of patients in any cohort are in Table 1. In the TN cohort, Grade ≥3 AEs in ≥10% of patients were neutropenia (33%) and pneumonia (11%). Serious AEs (SAEs) occuring in ≥2 patients included pneumonia (Grade 3, n=2 [11%]) and pyrexia (Grade 1, n=2 [11%]). One patient had pulmonary alveolar hemorrhage (Grade 4, investigator assessed as related to acalabrutinib) leading to discontinuation of study treatment (acalabrutinib + BR). There were 3 deaths: 1 patient had Grade 5 pneumonitis (investigator assessed as related to acalabrutinib; 24 days after last dose), 1 died of unascertained cause, and 1 died of unknown cause. In the R/R cohort, Grade ≥3 AEs (in ≥10%) were neutropenia (50%); diarrhea, leukopenia, decreased neutrophil count, pneumonia and thrombocytopenia (10% each). Pneumonia was the only SAE to occur in ≥2 patients (n=3; 1 Grade 1, 2 Grade 3). Three patients had major hemorrhage; all were Grade 3 AEs and investigator assessed as unrelated to study treatment (subdural hematoma [after a traumatic fall], large intestinal ulcer hemorrhage [on study day 2], gastrointestinal hemorrhage [duodenal tumor found on endoscopy]). One patient had Grade 3 angina pectoris (unrelated) leading to discontinuation of study treatment (acalabrutinib + BR). There were 4 deaths: 1 patient had Grade 5 AE cerebrospinal meningitis (investigator assessed as unrelated to acalabrutinib; 123 days after last dose), 1 died of unascertained cause, and 2 had PD. No patients had cytomegalovirus infection, pneumocystis jiroveci pneumonia, or atrial fibrillation during the study. In the TN cohort, the ORR was 94%, with a CR rate of 72% (Table 2); median DOR and median PFS were not reached (NR). In the R/R cohort, ORR was 80% and CR rate was 65%; median DOR was 15.0 mo (95% CI: 12.2, NR) and median PFS was 16.6 mo (95% CI: 14.2, NR). There were no clinically meaningful differences in steady-state acalabrutinib exposure when administered with or without BR (n=12 [TN, n=6; R/R, n=6]). Conclusion: Combination therapy with acalabrutinib + BR showed an acceptable safety profile, with no meaningful changes in acalabrutinib exposure. The high CR rate with acalabrutinib + BR in both TN and R/R MCL further supports a phase 3 randomized study of acalabrutinib + BR versus BR in TN MCL (NCT02972840). Disclosures Phillips: Bayer: Consultancy; Seattle Genetics: Consultancy; Pharmacyclics: Consultancy, Research Funding; Abbvie: Research Funding; Genentech: Consultancy; Gilead: Consultancy. Smith:Portola: Research Funding; Merck Sharpe Dohme and Corp: Consultancy, Research Funding; Acerta Pharma BV: Research Funding; Pharmacyclics: Research Funding; Genentech: Research Funding; Seattle Genetics: Research Funding. Jurczak:Afimed: Research Funding; BeiGene: Research Funding; Celgene: Research Funding; Epizyme: Research Funding; Gilead: Research Funding; Janssen: Research Funding; Nordic Nanovector: Research Funding; Merck: Research Funding; Morphosys: Research Funding; Pharmacyclics: Research Funding; Servier: Research Funding; Roche: Research Funding; TG Therapeutics: Research Funding; Gilead: Consultancy; Janssen: Consultancy; Sandoz-Nowartis: Consultancy; AstraZeneca/Acerta: Consultancy, Research Funding; European Medicines Agency: Consultancy. Robak:AbbVie, Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Stevens:Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees. Farber:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Research Funding; Acerta: Research Funding; Pharmacyclics: Research Funding; Genentech: Honoraria, Research Funding, Speakers Bureau; Charles M. Farber, MD, PhD, LLC-Medical legal consulting: Consultancy; ummit Medical Group-MD Anderson Cancer Center: Employment; Gilead: Honoraria; Seattle Genetics: Honoraria, Speakers Bureau. Pagel:Pharmacyclics, an AbbVie Company: Consultancy; Gilead: Consultancy. Maddocks:Merck: Research Funding; Pharmacyclics: Research Funding; Novartis: Research Funding; Pharmacyclics/Janssen: Honoraria; AstraZeneca: Honoraria; Teva: Honoraria; BMS: Research Funding. Flinn:Janssen: Research Funding; Trillium: Research Funding; Calithera: Research Funding; Celgene: Research Funding; Forma: Research Funding; Verastem: Research Funding; Pfizer: Research Funding; Takeda: Research Funding; BeiGene: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; Novartis: Research Funding; Forty Seven: Research Funding; Constellation: Research Funding; Genentech: Research Funding; Agios: Research Funding; Infinity: Research Funding; Merck: Research Funding; Verastem: Consultancy, Research Funding; TG Therapeutics: Research Funding; Portola: Research Funding; Gilead: Research Funding; Kite: Research Funding; Incyte: Research Funding; ArQule: Research Funding; Curis: Research Funding. Jedrzejczak:BMS: Research Funding; Astellas: Research Funding; Onconova: Research Funding; Amgen: Research Funding; Polish Ministry of Higher Education and Science: Research Funding; Takeda: Honoraria, Research Funding; Abbvie: Honoraria; Roche: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria; Novartis: Honoraria, Research Funding; Janssen Cilag: Honoraria; Polish Parliament: Consultancy; Polish Ministry of Health: Consultancy; Medical University Warsaw, Central Hospital Warsaw: Employment; Astex: Research Funding; AstraZeneca: Research Funding. Goy:Seattle Genetics: Research Funding; Genentech: Research Funding; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Acerta: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pharmacyclics/J&J: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Hackensack University Medical Center: Employment; COTA: Membership on an entity's Board of Directors or advisory committees. Zinzani:MSD: Honoraria, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Speakers Bureau; Celltrion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau;

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
行不行完成签到,获得积分10
2秒前
2秒前
尚認徒图发布了新的文献求助10
3秒前
lujibaqi发布了新的文献求助10
4秒前
4秒前
369ninja发布了新的文献求助10
4秒前
行不行发布了新的文献求助10
5秒前
热情的觅云完成签到 ,获得积分10
5秒前
诃德发布了新的文献求助10
5秒前
dxxxxx发布了新的文献求助30
5秒前
6秒前
ff完成签到,获得积分10
6秒前
果果发布了新的文献求助10
7秒前
7秒前
科目三的应助被Sia采纳,获得30
8秒前
优美世倌发布了新的文献求助10
8秒前
8秒前
斯文败类的应助被可乐采纳,获得10
8秒前
9秒前
10秒前
drizzle发布了新的文献求助10
11秒前
11秒前
lkk发布了新的文献求助10
12秒前
木木发布了新的文献求助10
12秒前
坚强枫完成签到,获得积分10
12秒前
徐枘发布了新的文献求助10
13秒前
潮汐完成签到 ,获得积分10
13秒前
13秒前
时静完成签到 ,获得积分10
14秒前
张君发布了新的文献求助10
15秒前
8o7XJ7发布了新的文献求助10
15秒前
Allen0520发布了新的文献求助30
15秒前
16秒前
小蘑菇的应助被hsn采纳,获得10
16秒前
星辰大海的应助被二甲双胍采纳,获得10
16秒前
我是谁的应助被汤包采纳,获得30
17秒前
充电宝的应助被yjt采纳,获得10
17秒前
郭元强完成签到,获得积分10
18秒前
18秒前
LLJ完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784